

**DMD # 86249**

---

**Development of a gold nanoparticle-functionalized surface plasmon resonance assay for the sensitive detection of monoclonal antibodies and its application in pharmacokinetics**

Haihong Bai<sup>1</sup>, Mei Yuan<sup>2</sup>, Xiaojing Wang<sup>3</sup>, Xinghe Wang<sup>1\*</sup>, Jinjing Che<sup>2\*</sup>

Phase I Clinical Trial Center, Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, PR China (HB, XGW); State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100085, PR China (MY, JJC); Chinese Pharmaceutical Association, Beijing 100022, PR China (XJW)

\*These authors contributed equally to this work

**DMD # 86249**

---

**Running title:** Au-NP SPR for pharmacokinetics

**Corresponding Author**

Jinjing Che

Beijing Institute of Pharmacology and Toxicology ,No. 27 Taiping Road, Haidian Distrcet,Beijing,  
China

Tel and Fax number: 86-010-66930633

Email: chejinjing80@126.com

**Number of Text Pages:** 41

**Number of Tables:** 6

**Number of Figures:** 5

**Number of References:** 46

**Number of Words in Abstract:** 226

**Number of words in Introduction:** 738

**DMD # 86249**

---

**Number of Words in Discussion:** 1431

**ABBREVIATIONS:**C225, cetuximab; LLOQ, lower limit of quantitation; MAbs, monoclonal antibodies; SPR, surface plasmon resonance; NP, nanoparticle.

## DMD # 86249

---

### Abstract

As a prominent human therapeutic, therapeutic monoclonal antibodies (mAbs) have attracted increasing attention in the past decade due to their high targeting specificity, low toxicity, and prolonged efficacy. Systematic pharmacokinetic analysis of mAbs not only largely facilitates the understanding of their biological functions but also promotes the development of therapeutic drug discovery, early clinical trial implementation and therapeutic monitoring. However, the extremely complex nature of biomatrices and the especially low dosages of mAbs make their detection in biomatrices and further pharmacokinetic analysis highly challenging. Therefore, a method capable of reliably, quickly and sensitively quantifying mAbs in biomatrices is urgently needed. Herein, we developed and evaluated an Au NP-functionalized surface plasmon resonance (SPR) assay for C225 (cetuximab) detection and pharmacokinetic analysis in rhesus monkeys. Combining its advantages of label-free pretreatment and amplified signal response, the lower limit of quantitation (LLOQ) of C225 in monkey serum was reduced to 0.0125  $\mu\text{g/mL}$ , and the linear range had an order of magnitude comparable to that of an ELISA-based method. Furthermore, the pharmacokinetics of C225 in rhesus monkeys were studied after intravenous infusions of single doses at 7.5, 24 and 75 mg/kg. The concentration of C225 in monkey serum was detectable after dosing for 720 h. We believe that this new strategy will be applicable as a general protocol for mAb quantification, pharmacokinetic characteristic determination, and toxicokinetic analysis during drug development.

## **Introduction**

Currently, nearly 350 monoclonal antibodies (mAbs) are being investigated in clinical trials of different stages (Wang et al., 2016; Singh et al., 2018). Despite remarkable advances, the absorption, distribution, metabolism, and elimination of mAbs, early clinical trial development and therapeutic monitoring, have not been completely elucidated. For example, considerable controversy exists regarding whether the Fc receptor is the main factor for tuning mAb pharmacokinetics (Gurbaxani et al., 2013). The pharmacokinetics (PK) of immunoglobulin G (IgG) molecules are complex, involving protective and clearance pathways related to neonatal Fc receptor (FcRn)-dependent recycling, target-mediated drug disposition (TMDD), nonspecific or off-target binding-mediated clearance (CL), and sometimes immunogenicity (Piche-Nicholas et al., 2018). To obtain parameters to further elucidate the pharmacokinetic, toxicokinetic and clinical properties of mAbs, a method capable of reliable, fast and sensitive mAb quantification is urgently needed (Fischer et al., 2012; Li et al., 2016; Hage et al., 2018).

ELISA is currently one of the most prominent platforms for mAb quantification (Wolf et al., 2011; Salomon and Singh, 2015; Passot et al., 2017). ELISA pretreatment includes coating capture antibody, washing, and addition of sample, detection antibody, TMB and stop solution. This process generally takes 12-16 hours. The time-consuming ELISA pretreatment steps are major disadvantages and disrupt the fast and sensitive monitoring of mAbs in real time from early to late stages of drug development (Neill et al., 2015; Legeron et al., 2017). SPR is based on the principle that variation in the concentration of molecules in the solution may alter the

**DMD # 86249**

---

refractive index of the solution close to the sensor surface (Hamilton et al., 2012; Then et al., 2017; Jung et al., 2018). Biomolecular interaction analysis from Biacore using the optical SPR phenomenon can measure biomolecules in real time without requiring labeling or pretreatment (Fee, 2013; Olaru et al., 2015). Our group first reported a method for the quantification of C255 (cetuximab), a mAb (IgG1) directed at the extracellular domain of the receptor and further pharmacokinetic analysis of monkey serum using the Biacore system (Che et al., 2009). Although automated and accurate analysis was achieved, the relatively low detection sensitivity remained a major disadvantage of the method. The high-throughput detection and precise pharmacokinetic analysis of mAbs in complex biological samples are prevented because mAbs generally exist in extremely low amounts and remain undetectable at specific time points after dosing (Li et al., 2012).

Various methods have been developed to enhance the sensitivity of SPR biosensors (Jazayeri et al., 2016; Chen et al., 2018; Hong et al., 2018; Hossain and Maragos, 2018). One of the frequently adopted procedures is to improve the signal intensity of the analyst by changing the refractive index at the sensor surface by introducing other chemical or nanoparticle (NP) agents, including secondary antibodies, antibody-enzyme conjugates, and metal NPs (Jazayeri et al., 2016; Chen et al., 2018; Hossain and Maragos, 2018). Gold nanoparticles (Au NPs), have been widely used to amplify the responses of SPR biosensors due to the large shift in the plasmon angle, the broadened plasmon resonance, and the extremely high biocompatibility. Zhang et al. (2016) enhanced the bipyramidal Au NP-containing sensor compared with the

## DMD # 86249

---

NP-free system in the label-free detection of the analyte IgG. Ben et al. (2017) developed a stable Au NP bioconjugate for the detection of staphylococcal enterotoxin A using localized SPR, and the limit of detection was estimated to be 5 ng/mL, which was substantially lower than that obtained using a quartz crystal microbalance. Few reports on mAb quantification in complex biomatrices for pharmacokinetic analysis using Au NP-functionalized SPR exist to the best of our knowledge.

We elucidated the preclinical pharmacokinetic parameters of C225 in rhesus monkeys after intravenous infusion for the first time using an SPR biosensor-based method (Che et al., 2009). However, the lower of limit of quantification (LLOQ) of the method was 0.05  $\mu\text{g/mL}$ . In this study, we further developed and evaluated an Au NP-functionalized SPR assay for C225 detection and pharmacokinetic analysis in rhesus monkeys. Combining the advantages of label-free pretreatment and amplified signal response, the LLOQ was lowered to 0.0125  $\mu\text{g/mL}$ , and the linear range had an order of magnitude comparable to that of an ELISA-based method. Therefore, the concentration of C225 in monkey serum after intravenous injection for longer time was detectable. Furthermore, accurate pharmacokinetic parameters of C225 in rhesus monkeys were obtained. As a result, we believe that this new strategy will be applicable as a general protocol for mAb quantification, elucidating pharmacokinetic and toxicokinetic analysis during drug development.

## Materials and Methods

### *Chemicals and Reagents*

**DMD # 86249**

---

C225, Erbitux and EGFR were provided by Huabei Pharmaceutical Factory (Hebei Province, China). Goat anti-human IgG and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Proclin 300, 3,3',5,5'-Tetramethylbenzidine (TMB) and 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propane sulfonate (CHAPS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). HRP conjugated anti-goat IgG antibody were acquired from Bethyl (Montgomery, USA). The Biacore T200 biosensor, amine coupling kit, CM5 sensor chip, 10 mM acetate, 50 mM NaOH, glycine-HCl (pH 2.0), ethanolamine, and ethanolamine-HCl were purchased from Biacore AB (Uppsala, Sweden). N-hydroxysuccinimide (NHS) and N-ethyl-N'-(3-diethylaminopropyl) carbodiimide (EDC) were purchased from Pierce (Rockford, IL, USA). The deionized water (with resistance > 18 M $\Omega$ . cm) used in this experiment was prepared using a Millipore purification system (Billerica, MA, USA).

***Synthesis of Goat Anti-human IgG-Au NP Conjugates***

Briefly, 0.75, 1 and 3 mL of 1% trisodium citrate solution was added to 100 mL of 0.01% HAuCl<sub>4</sub> solution, and the mixture was allowed to react at 100 °C for 5-30 min with vigorous stirring to obtain the Au NPs with the desired diameters.

Then, 20 mL of 15  $\mu$ g/mL goat anti-human IgG (pH 9.0) was added to 20 mL of the obtained Au NP solution (pH 9.0), and the mixture was stirred for 10 min at ambient temperature. Finally, 200 mg of BSA was added, and the solution was centrifuged at 12,000 $\times$  g for 60 min to remove any unbound molecules. The obtained goat anti-human IgG-Au NP conjugates were

**DMD # 86249**

---

stored at 4 °C for further use.

***Au NP-functionalized SPR Assay for C225 Quantification in Monkey Serum***

All SPR measurements were performed on a Biacore T200 instrument (Biacore AB, Uppsala, Sweden) using HBS-EP buffer (0.01 M HEPES (pH 7.4), 0.15 M NaCl, 3 mM EDTA, 0.005% Tween 20) as the running buffer at a flow rate of 10  $\mu$ L/min. The Fc1 of the CM 5 sensor chip was used for EGFR immobilization using the amine coupling kit according to the manufacturer's protocol, and Fc2 served as the reference. Next, 30  $\mu$ L of EGFR (100  $\mu$ g/mL dissolved in 10 mM NaOAc (pH 4.5)) was injected and allowed to covalently couple to the sensor surface. Then, the unreacted sites were blocked by the injection of 35  $\mu$ L of 1 M ethanolamine (pH 8.5). For quantitative analysis, 20  $\mu$ L of C225 at different concentrations in 20% monkey serum and 60  $\mu$ L of goat anti-human IgG-Au NP conjugates were injected and allowed to flow over the immobilized EGFR sensor surface and the reference flow cell at room temperature sequentially. The unbound goat anti-human IgG-Au NPs were removed by HBS-EP buffer. Data from the reference flow cell were subtracted to correct for nonspecific binding. The sensor surface was regenerated by injecting 10  $\mu$ L of 10 mM HCl (pH 2.0), followed by a return to HBS-EP buffer.

***Method Validation***

The established method was validated for a calibration curve, sensitivity, matrix effects,

**DMD # 86249**

---

precision, accuracy and stability according to the Food and Drug Administration (FDA) guidelines for bioanalytical method validation. The calibration curve for C225 ranging from 0.0125 to 3.2  $\mu\text{g/mL}$  in 20% monkey serum was generated by plotting the Biacore response of the analyte versus the nominal concentration and fitted by a four-parameter sigmoidal model as described in our previous work (Che et al., 2009). C225 at concentrations of 0.025, 0.4 and 1.6  $\mu\text{g/mL}$  were set as the low, middle and high quality control (QC) samples, respectively. The three QC samples were assayed at the beginning and end of 100 cycles to evaluate the changes in the coherence of the CM 5 sensor chip surface after multiple regenerations. The sensitivity of the method was evaluated in terms of LLOQ, which was determined by the criteria that the Biacore response of C225 at the LLOQ was at least 5 times that of the blank and the accuracy (relative error) of five replications was within the scope of 80-120%. Intraday precision and accuracy were employed to study the repeatability and reproducibility of the developed method. For intraday variability assessment, three QC samples were analyzed in sextuplicate during a single day; for the interday test, three QC samples were analyzed over five consecutive days. The precision was expressed as the coefficient of variation (CV) relative to the overall mean observed concentration for all analytical runs at each concentration, and the accuracy was determined as the percentage of the overall mean measured concentrations versus the corresponding nominal concentration. The specificity of the assay was validated by adding C225 at a final concentration of 0.4  $\mu\text{g/mL}$  to 50% human serum, 50% Sprague Dawley rat serum, and 20% pooled monkey serum containing the chimeric recombinant anti-CD20 monoclonal antibody (0.4  $\mu\text{g/mL}$ ), human

## DMD # 86249

---

$\gamma$ -globulin (0.4  $\mu\text{g/mL}$ ) and chimeric recombinant her 2 antibody (0.4  $\mu\text{g/mL}$ ), respectively. Each sample was measured in triplicate, and the accuracy was calculated to evaluate the influence of the investigated matrix on the quantitative analysis of C225.

### ***ELISA based assay for C225 quantification in monkey serum***

A 96-well plate was coated with the EGFR diluted with 0.05 M carbonate-bicarbonate buffer (pH 9.6) at a protein weight of 2 $\mu\text{g/ well}$ . Wells without antigen were prepared as the blank controls. The plates were incubated at 4°C overnight for antigen adsorption. After removal of the antigen solution by washing with PBST for three times, the wells were treated with 200  $\mu\text{L}$  PBS containing 10% bovine serum for blocking and incubated at room temperature for 2 h. After washed times with PBST, different concentration of C225 diluted by 10% monkey serum were added to the wells (100  $\mu\text{L/well}$ ) and incubated at room temperature for 1 h. The wells were continued washed with PBST for six times and HRP-conjugated goat anti-human IgG diluted by 1:20000 (100  $\mu\text{L/well}$ ) were added as the secondary antibody for incubation at room temperature for 1 h. Color development was performed with TMB peroxidase substrate (100  $\mu\text{L/well}$ ) for 15min, followed by addition of a stopping solution (0.25N  $\text{H}_2\text{SO}_4$ , 100  $\mu\text{L/well}$ ). The optical density (OD) values at 450 nm were measured and the final OD values were derived by subtracting the values for wells without antigen from those for wells with antigen.

### ***Application to Pharmacokinetic Analysis in Rhesus Monkeys***

Rhesus monkeys were obtained from the Laboratory Animal Center of the Academy of

## DMD # 86249

---

Military Medical Sciences. The animal room was set at a controlled temperature ( $25 \pm 1$  °C) and humidity ( $55 \pm 5\%$ ) and a 12 h light/dark cycle. The animals were fed a standard diet and had free access to water. All experiments were approved by the Institutional Ethical Committee for Care and Use of Laboratory Animals of Academy of Military Medical Sciences and performed in accordance with the Guide for the Care and Use of Laboratory Animals. Nine rhesus monkeys (weighing  $4.3 \pm 0.7$  kg) were divided into three equal groups (2 males and 1 female in each group) by a randomization method and received doses of C225 (7.5, 24, or 75 mg/kg) via a 30 min intravenous infusion. The blood samples were collected from the femoral veins of the animals using a puncture needle at 0, 0.167, 0.333, 0.5 h during the intravenous infusion and at 1, 4, 8, 12, 24, 72, 120, 168, 216, 264, 312, 360, 456, 504, 552, 648 and 720 h after dosing. Freshly collected whole blood (approximately 2 mL) at each time point was collected in a tube and immediately centrifuged ( $4500 \times g$  for 10 min at 4 °C) for serum separation. All the serum samples were kept at -80 °C before analysis. The pharmacokinetic parameters of C225 were fitted using noncompartmental models by WinNonlin.

## Results and Discussion

### *Construction of the Au NP-functionalized SPR Assay for mAb Detection*

SPR sensors have gained increasing attention in the past decade due to the urgent need for fast, reliable and label-free methods for mAb detection and quantification in the fields of

**DMD # 86249**

---

molecular biology, pharmacology and other life sciences. However, a major challenge preventing the technology from being successfully translated to pharmacokinetic analysis is its relatively high LLOQ. Au NPs can amplify the SPR signal by altering the SPR angle due to resonance coupling between the surface plasma wave of the Au NP itself and the Au film on the chip, which further changes the refraction rate on the surface of the chip. Therefore, an Au NP-functionalized SPR assay was developed for the sensitive detection of mAbs, and the procedure is illustrated in Scheme 1. The successful synthesis of Au NPs and goat anti-human IgG-Au NP conjugates was evaluated by transmission electron microscopy (TEM) and ultraviolet (UV) spectrophotometry, respectively. The morphologies of the three prepared Au NP baths were spherically uniform in shape with average diameters of 11.2 nm, 38.7 nm and 53.1 nm, and no obvious cluster phenomena were observed. After coupling with goat anti-human IgG via electrostatic interactions between the Au NPs and antibodies, the maximum UV absorption wavelengths of the 10 nm, 30 nm and 50 nm colloidal Au solutions were shifted from 518 nm to 527 nm, from 522 nm to 532 nm and from 531 nm to 540 nm due to protein absorption on the surface of the Au NPs. The results of our work have been published (Shi et al., 2012).

The particle diameter of Au NPs, which is crucial for enhancing the signal responses of C225 in the SPR sensor, was also investigated by injecting goat anti-human IgG-Au NP conjugates prepared with 10 nm, 30 nm and 50 nm colloidal Au particles in the manual injection mode. The Au NP-functionalized SPR sensor with 10 nm colloidal Au particles yielded the highest signal amplification and the lowest background signal compared with the 30 nm and 50

**DMD # 86249**

---

nm colloidal Au particle-based assays. The results of our work have been published (Shi et al., 2012).

Au NPs of different sizes resulted in various levels of signal enhancement, as the recognition sites on the antibody were limited, and small Au NPs possessed the advantage of better surface diffusion (Li et al., 2013). Furthermore, Fernandez et al. (2012) reported that small Au NPs have better diffusion kinetics, favoring their access to the surface (Yuan et al., 2008). The authors also reported that signal enhancement was due to not only Au NPs but also to IgG molecules around the NPs, since more IgG molecules around the NPs increased the overall size. Moreover, IgG molecules around the NPs may also increase the chances of NPs binding to the surface, contributing to the signal enhancement observed. In our study, the number of IgG molecules bound to Au NPs was estimated by the amount of color remaining in the supernatant, as the supernatant was red, while the aggregation of NPs was blue. The 10 nm Au NPs absorbed the most IgG molecules in our study (Shi et al., 2012), which was consistent with the report that NP aggregation results in a significant red shift, changing the solution color from red to blue due to interparticle plasmon coupling (Su et al., 2003; Srivastava et al., 2005).

Therefore, 10 nm colloidal Au particles were adopted for functionalization of the SPR sensor and the sensitive detection of trace amounts of mAbs.

***Validation of the Au NP-functionalized SPR Quantitative Assay for C225 in Monkey Serum***

### *Calibration curve and LLOQ*

In our study, calibration standards were prepared and analyzed at nine different concentrations ranging from 0.0125 to 3.2  $\mu\text{g/mL}$ . The calibration curve was constructed by plotting the signals of the Biacore instrument (RU) against the log of the analyte concentrations and then fitted to a four-parameter sigmoid model (Fig. 1). The model fit well to the C225 standard curve over the concentration range. However, the C225 calibration curve ranged from 0.0125-0.4  $\mu\text{g/mL}$  for only the ELISA-based method (Fig. 1).

To determine the LLOQ of the developed assay, C225 at the concentration of 0.0125  $\mu\text{g/mL}$  was assayed five times, and the results are listed in Table 1. The precision and accuracy of the assay were calculated as 12.60% and 108.80%, respectively. However, three of the five samples were undetectable at the concentration of 0.00625  $\mu\text{g/mL}$ . Therefore, the LLOQ of the assay developed for C225 was defined as 0.0125  $\mu\text{g/mL}$  according to the validation criteria for analytical methods. The LLOQ was four times lower than that of the nanoparticle-free SPR-based assay developed in our previous study (0.05  $\mu\text{g/mL}$ ).

Depending on the SPR system, the sensitivity and curve dynamic range reached can be lower than those of microplate-based ELISA methods. In previous works, we proved that the LLOQ of the NP-free SPR-based assay was only 0.05  $\mu\text{g/mL}$  (Che et al., 2009). Improvement of the SPR sensitivity and curve dynamic range can be accomplished by different strategies. For example, the LLOQ can be improved using secondary antibodies (Gobi, 2007; Yuan et al., 2007; Mizuta et al., 2008), and immunoreagents can also be coupled to other elements that increase

## DMD # 86249

---

their mass and refractive index, such as liposomes (Wink et al., 1998), enzymes (Yang and Kang, 2008; Mitchell and Lowe, 2009), polystyrene NPs (He et al., 2004), magnetic NPs (Teramura et al., 2006), and Au NPs (Lyon et al., 1998; Mitchell et al., 2005; Cao and Sim, 2007). The use of Au NPs has generated substantial interest due to the possibility of controlling their size (Daniel and Astruc, 2004; Boisselier and Astruc, 2009; Li-Na et al., 2010). It has also been postulated that Au NPs may enhance the sensitivity and curve dynamic range via their own SPR properties (LSPR, localized surface plasmon resonance) reinforcing the signal by means of electronic coupling of the surface and NP plasmons (Lyon et al., 1998, 1999; Chah et al., 2001).

Methods with better sensitivity and a standard curve dynamic range are good for accurate quantification, as they can detect lower concentrations and require a lower dilution factor. Therefore, the pharmacokinetic parameters from our method were more reliable than SPR without gold nanoparticle.

### *Baseline Stability*

Three QC samples at a high concentration (1.6  $\mu\text{g/mL}$ ), a medium concentration (0.4  $\mu\text{g/mL}$ ) and a low concentration (0.025  $\mu\text{g/mL}$ ) were freshly prepared with 20% rhesus monkey serum and tested in the first and 100<sup>th</sup> cycles to evaluate alterations in the binding abilities of the CM5 chip to EGFR. Fig. 2 (a) shows that EGFR immobilized onto the sensor chip could withstand at least 100 regeneration cycles without significantly changing the baseline (less than 7.8%) using 10 mM glycine-HCl (pH 2.5), and the changes in the binding capacities of the three different concentrations of C225 were less than 12% from the beginning to the completion of the

**DMD # 86249**

---

100 regenerations (Fig. 2(b)).

*Precision and Accuracy*

Three QC samples at a high concentration (1.6  $\mu\text{g/mL}$ ), medium concentration (0.4  $\mu\text{g/mL}$ ) and low concentration (0.025  $\mu\text{g/mL}$ ) were used to investigate the intraday and interday precision and accuracy of the developed assay. As shown in Tables 2 and 3, the precision evaluations with CV ranged from 4.31% to 13.20% (intraday, n=6) and from 6.75% to 9.77% (interday, n=5). The accuracy ranged from 96.67% to 104.83% (intraday, n=6) and from 96.0% to 109.26% (interday, n=5). These results demonstrate that the developed assay possesses good accuracy and precision for C225 detection in monkey serum.

*Specificity of the assay*

The specificity of the assay was determined by comparing the calculated concentrations of C225 in five different matrices with the nominal values. The precision values ranged from 6.25% to 14.47%, and the accuracy values ranged from 106.0% to 114.5% (n=3) in the listed matrix (Table 4). These results indicate that this assay has good specificity and little interference for C225 detection in several types of matrices, which is especially beneficial for quantitatively analyzing C225 in different biological samples.

In summary, the above results indicate that the newly developed Au NP-functionalized SPR assay displays a wider calibration curve and a higher sensitivity. Therefore, the assay is

more suitable for C225 detection in complex matrices. To the best of our knowledge, this is the first study to report an Au NP-functionalized SPR sensor for mAb quantification using a validated method. Validation experiments show this method to be sensitive, accurate, reproducible and specific.

### ***Pharmacokinetic Study in Rhesus Monkeys***

Pharmacokinetically analyzing mAbs is challenging because they are usually administered at small dosages during target therapy and need to be monitored for an extended period after dosing. Inspired by the sensitive detection of C225 with the Au NP-functionalized SPR assay, the method was further applied to the pharmacokinetic analysis of C225 in rhesus monkeys following single intravenous infusions of low (7.5 mg/kg), medium (24 mg/kg) and high doses (75 mg/kg). The serum concentration-time profiles are shown in Fig. 3. The concentrations of C225 in monkey serum after intravenous injection for 504 h in the low-dose group (7.5 mg/kg) and for 720 h in the high-dose group (75 mg/kg) were detected as  $0.12 \pm 0.01$   $\mu\text{g/mL}$  and  $4.50 \pm 0.28$   $\mu\text{g/mL}$  (n=3), respectively. However, the concentration of C225 was detected at only 456 h after dosing by our previously established NP-free SPR system ((Che et al., 2009). The prolonged monitoring time of C225 in the sera of rhesus monkeys after dosing could contribute to the improved sensitivity of the Au NP-functionalized SPR due to the introduction of Au NPs in the sensor. Therefore, the pharmacokinetic parameters were more reliable than SPR without gold nanoparticle .

**DMD # 86249**

---

Next, the major pharmacokinetic parameters were calculated based on weighted regression analysis. The concentrations of C225 at the same time point increased as the dose increased. The terminal phase elimination half-life values ( $t_{1/2}$ ) were  $33.15 \pm 1.82$  h,  $48.03 \pm 0.69$  h, and  $55.72 \pm 0.73$  h for the three doses, respectively. The  $T_{1/2}$  was significantly prolonged as the dosage increased. The mean residence time (MRT) was improved from  $105.11 \pm 4.78$  h to  $152.84 \pm 6.83$  h, and the area under the curve ( $AUC_{(0-t)}$ ) was enhanced from  $16390 \pm 1201.8$   $\mu\text{g} \cdot \text{h} \cdot \text{mL}^{-1}$  to  $263091 \pm 30698$   $\mu\text{g} \cdot \text{h} \cdot \text{mL}^{-1}$  as the dosage increased. However, the clearance (CL) values were  $0.459 \pm 0.03$   $\text{mL} \cdot \text{h}^{-1} \cdot \text{kg}^{-1}$ ,  $0.466 \pm 0.01$   $\text{mL} \cdot \text{h}^{-1} \cdot \text{kg}^{-1}$  and  $0.29 \pm 0.03$   $\text{mL} \cdot \text{h}^{-1} \cdot \text{kg}^{-1}$  for the low-, medium-, and high-dose groups, which decreased as the dosage increased. Therefore, the pharmacokinetics of C225 were in accordance with the nonlinear model in the investigated dosage range in rhesus monkeys (7.5-75 mg/kg).

While there are some reports (Skottrup et al., 2007) on the clinical pharmacokinetic profile of Erbitux (originator of C225), there are no reports on the quantitation of Erbitux in monkey serum or on its preclinical pharmacokinetic parameters.

In our study, use of the ELISA and Au NP SPR methods for the quantitation of C225 in rhesus monkeys serum was validated in accordance with guidelines established by the Bioanalytical Method Validation Guidance for Industry by the FDA and included analyses of the calibration curves, sensitivity, matrix effects, precision, accuracy and stability. According to the guidelines, SPR, except for ELISA, is the method recommended for ligand binding analysis. While both methods were shown to be capable of analyzing the pharmacokinetics of C225 in

## DMD # 86249

---

rhinus monkeys, the calibration curve of C225 ranged from 0.0125 to 0.4  $\mu\text{g/mL}$  by the ELISA method and from 0.0125 to 3.2  $\mu\text{g/mL}$  by the Au NP SPR method.

The Au NP-functionalized SPR assay was further applied to the pharmacokinetic analysis of C225 in rhinus monkeys following single intravenous infusions of low (7.5 mg/kg), medium (24 mg/kg) and high doses (75 mg/kg), and the major pharmacokinetic parameters were compared to those of the NP-free SPR method (Che et al., 2009). Due to the more sensitive LLOQ of the Au NP-functionalized SPR assay, the time point for detecting C225 in rhinus monkey serum after dosing was prolonged to 504 h in the medium-dose group (24 mg/kg) and to 720 h in the high-dose group (75 mg/kg); the detectable time point in the low-dose group (7.5 mg/kg) was 456 h for both methods. However, the concentration of C225 was detected at only 456 h after dosing (low, medium, high dose) by our previously established NP-free SPR system. As a result, the  $t_{1/2}$  values of C225 in rhinus monkeys obtained by the two methods were not significantly different at the dosage of 7.5 mg/kg ( $p>0.05$ ) but were significantly different at dosages of 24 mg/kg and 75 mg/kg ( $p<0.05$ ) due to the higher sensitivity of the Au NP-functionalized SPR assay and the prolonged detection times.

The fact that the NP-free SPR-based assay was applied to the pharmacokinetic analysis of Erbitux as well as C225 and that the pharmacokinetic parameters of the two mAbs were not statistically different (Supplemental Fig. 1) prove that the SPR method can be applied to different antibodies. Currently, studies on use of the Au NP-functionalized SPR assay for analyses of Erbitux as well as other mAbs are ongoing.

## Conclusions

**DMD # 86249**

---

An Au NP-functionalized SPR quantitative assay for the sensitive detection of C225 was developed and validated. The assay displayed a wider calibration curve than the ELISA-based method and had a higher sensitivity than the nanoparticle-free SPR sensor due to the introduction of Au NPs to the SPR sensor, which altered the SPR angle and refraction rate on the surface of the chip via resonance coupling between the surface plasma wave of the Au NP itself and the Au film on the chip. The method was further applied for the pharmacokinetic analysis of C225 in rhesus monkeys in the low- (7.5 mg/kg), middle- (24 mg/kg), and high-dose groups (75 mg/kg). The concentration of C225 in monkey serum after intravenous injection for 504 h in the low-dose group was detectable, and the pharmacokinetics of C225 obtained from weighted regression analysis was accordant with the nonlinear model in the investigated dosage range in rhesus monkeys (7.5-75 mg/kg). These results indicate that the established method is sensitive, accurate, reproducible and specific for the detection of mAbs and may have more applications in pharmaco- and toxicokinetic characteristic analyses and clinical evaluations in the future.

**Authorship contributions**

*Participated in research design:* X.H. Wang and Che.

*Conducted experiments:* Bai, Yuan and Che.

*Contributed new reagents or analytic tools:* X.J. Wang, Bai and Yuan.

*Performed data analysis:* X.J. Wang, Bai, Yuan and Che.

*Wrote or contributed to the writing of the manuscript:* Bai and Che.

## References

- Ben HM, Hu D, Salmain M, Zhang L, Peng C, Wang Y, Liedberg B, and Boujday S (2017) Gold nanoparticle-based localized surface plasmon immunosensor for staphylococcal enterotoxin A (SEA) detection. *Anal Bioanal Chem* 409: 6227-6234.
- Boisselier E and Astruc D (2009) Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. *Chem Soc Rev* 38: 1759-1782.
- Cao C and Sim SJ (2007) Signal enhancement of surface plasmon resonance immunoassay using enzyme precipitation-functionalized gold nanoparticles: a femto molar level measurement of anti-glutamic acid decarboxylase antibody. *Biosens Bioelectron* 22: 1874-1880.
- Chah S, Hutter E, Roy D, Fendler JH, and Yi J (2001) The effect of substrate metal on 2-aminoethanethiol and nanoparticle enhanced surface plasmon resonance imaging. *Chem Phys* 272: 127-136.
- Che J, Wang H, Chen Z, Li X, Hou Y, Shan C, and Cheng Y (2009) A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor. *J Pharm Biomed Anal* 50: 183-188.
- Chen D, Mei Y, Hu W, and Li CM (2018) Electrochemically enhanced antibody immobilization on polydopamine thin film for sensitive surface plasmon resonance immunoassay. *Talanta* 182: 470-475.
- Daniel M-C and Astruc D (2004) Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and

- nanotechnology. *Chem Rev* 104: 293-346.
- Fee CJ (2013) Label-free, real-time interaction and adsorption analysis 1: surface plasmon resonance. *Methods Mol Biol* 996: 287-312.
- Fernandez F, Sanchez-Baeza F, and Marco MP (2012) Nanogold probe enhanced surface plasmon resonance immunosensor for improved detection of antibiotic residues. *Biosens Bioelectron* 34: 151-158.
- Fischer SK, Yang J, Anand B, Cowan K, Hendricks R, Li J, Nakamura G, and Song A (2012) The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: case studies. *MAbs* 4: 623-631.
- Gurbaxani B, Dostalek M, and Gardner I (2013) Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? *Mol Immunol* 56: 660-674.
- Hage C, Gremse F, Griessinger CM, Maurer A, Hoffmann SHL, Osl F, Pichler BJ, Kiessling F, Scheuer W, and Poschinger T (2018) Comparison of the accuracy of FMT/CT and PET/MRI for the assessment of antibody biodistribution in squamous cell carcinoma xenografts. *J Nucl Med* 59: 44-50.
- Hamilton RG, Saini SS, and MacGlashan D (2012) Surface plasmon resonance analysis of free IgE in allergic patients receiving omalizumab (Xolair). *J Immunol Methods* 383: 54-59.
- He L, Smith EA, Natan MJ, and Keating CD (2004) The distance-dependence of colloidal Au-amplified surface plasmon resonance. *J Phys Chem B* 108: 10973-10980.

**DMD # 86249**

---

Hong Y, Jo S, Park J, Park J, and Yang J (2018) High sensitive detection of copper II ions using D-penicillamine-coated gold nanorods based on localized surface plasmon resonance.

*Nanotechnology* 29: 215501.

Hossain MZ and Maragos CM (2018) Gold nanoparticle-enhanced multiplexed imaging surface plasmon resonance (iSPR) detection of *Fusarium* mycotoxins in wheat. *Biosens*

*Bioelectron* 101: 245-252.

Jazayeri MH, Amani H, Pourfatollah AA, Avan A, Ferns GA, and Pazoki-Toroudi H (2016)

Enhanced detection sensitivity of prostate-specific antigen via PSA-conjugated gold nanoparticles based on localized surface plasmon resonance: GNP-coated anti-PSA/LSPR as a novel approach for the identification of prostate anomalies. *Cancer Gene Ther* 23: 365-369.

Jung I, Kim M, Kwak M, Kim G, Jang M, Kim SM, Park DJ, and Park S (2018) Surface plasmon resonance extension through two-block metal-conducting polymer nanorods. *Nat*

*Commun* 9: 1010.

Legeron R, Xuereb F, Chaignepain S, Gadeau AP, Claverol S, Dupuy JW, Djabarouti S,

Couffinhal T, Schmitter JM, and Breilh D (2017) A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by

LC-MS/MS in human plasma comparing two internal standard calibration approaches. *J Chromatogr B Analyt Technol Biomed Life Sci* 1070: 43-53.

Li-Na M, Liu D-J, and Wang Z-X (2010) Synthesis and applications of gold nanoparticle probes.

*Chin J Anal Chem* 38: 1-7.

Li G, Li X, Yang M, Chen MM, Chen LC, and Xiong XL (2013) A gold nanoparticles enhanced surface plasmon resonance immunosensor for highly sensitive detection of ischemia-modified albumin. *Sensors (Basel)* 13: 12794-12803.

Li H, Ortiz R, Tran L, Hall M, Spahr C, Walker K, Laudemann J, Miller S, Salimi-Moosavi H, and Lee JW (2012) General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. *Anal Chem* 84: 1267-1273.

Li Y, Monine M, Huang Y, Swann P, Nestorov I, and Lyubarskaya Y (2016) Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies. *MAbs* 8: 1079-1087.

Lyon LA, Musick MD, and Natan MJ (1998) Colloidal Au-enhanced surface plasmon resonance immunosensing. *Anal Chem* 70: 5177-5183.

Lyon LA, Peña DJ, and Natan MJ (1999) Surface plasmon resonance of Au colloid-modified Au films: particle size dependence. *J Phys Chem B* 103: 5826-5831.

Mitchell JS and Lowe TE (2009) Ultrasensitive detection of testosterone using conjugate linker technology in a nanoparticle-enhanced surface plasmon resonance biosensor. *Biosens Bioelectron* 24: 2177-2183.

Mitchell JS, Wu Y, Cook CJ, and Main L (2005) Sensitivity enhancement of surface plasmon resonance biosensing of small molecules. *Anal Biochem* 343: 125-135.

**DMD # 86249**

---

- Mizuta Y, Onodera T, Singh P, Matsumoto K, Miura N, and Toko K (2008) Development of an oligo(ethylene glycol)-based SPR immunosensor for TNT detection. *Biosens Bioelectron* 24: 191-197.
- Neill A, Nowak C, Patel R, Ponniah G, Gonzalez N, Miano D, and Liu H (2015) Characterization of recombinant monoclonal antibody charge variants using OFFGEL fractionation, weak anion exchange chromatography, and mass spectrometry. *Anal Chem* 87: 6204-6211.
- Olaru A, Bala C, Jaffrezic-Renault N, and Aboul-Enein HY (2015) Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis. *Crit Rev Anal Chem* 45: 97-105.
- Passot C, Desvignes C, Ternant D, Bejan-Angoulvant T, Duveau AC, Gatault P, and Paintaud G (2017) Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. *Bioanalysis* 9: 1227-1235.
- Piche-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O'Hara DM, Tchistiakova L, and Katragadda M (2018) Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. *MAbs* 10: 81-94.
- Salomon PL and Singh R (2015) Sensitive ELISA method for the measurement of catabolites of antibody-drug conjugates (ADCs) in target cancer cells. *Mol Pharm* 12: 1752-1761.
- Shi H, Che J, Chen Z, Liu Y, Shan C, and Cheng Y (2012) Effect of Au NPs of different sizes on sensitivity of SPR-based quantification method. *Mil Med Sci* 36: 280-288.
- Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, and Chugh VK (2018) Monoclonal

- antibodies: a review. *Curr Clin Pharmacol* 13: 85-99.
- Skottrup P, Hearty S, Frøkiær H, Leonard P, Hejgaard J, O'Kennedy R, Nicolaisen M, and Justesen AF (2007) Detection of fungal spores using a generic surface plasmon resonance immunoassay. *Biosens Bioelectron* 22: 2724-2729.
- Srivastava S, Frankamp BL, and Rotello VM (2005) Controlled plasmon resonance of gold nanoparticles self-assembled with PAMAM dendrimers. *Chem Mater* 17: 487-490.
- Su KH, Wei QH, Zhang X, Mock JJ, Smith DR, and Schultz S (2003) Interparticle coupling effects on plasmon resonances of nanogold particles. *Nano Lett* 3: 1087-1090.
- Teramura Y, Arima Y, and Iwata H (2006) Surface plasmon resonance-based highly sensitive immunosensing for brain natriuretic peptide using nanobeads for signal amplification. *Anal Biochem* 357: 208-215.
- Then WL, Aguilar MI, and Garnier G (2017) Quantitative detection of weak d antigen variants in blood typing using SPR. *Sci Rep* 7: 1616.
- Wang J, Iyer S, Fielder PJ, Davis JD, and Deng R (2016) Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. *Biopharm Drug Dispos* 37: 51-65.
- Wink T, van Zuilen SJ, Bult A, and van Bennekom WP (1998) Liposome-Mediated Enhancement of the sensitivity in immunoassays of proteins and peptides in surface plasmon resonance spectrometry. *Anal Chem* 70: 827-832.
- Wolf J, Lachmann I, Wagner U, Osman AA, and Mothes T (2011) Quantification of human tissue

**DMD # 86249**

---

- transglutaminase by a luminescence sandwich enzyme-linked immunosorbent assay. *Anal Biochem* 419: 153-160.
- Yang G and Kang SW (2008) Detection of multi-class pesticide residues using surface plasmon resonance based on polyclonal antibody. *Food Sci Biotechnol* 17: 547-552.
- Yuan J, Oliver R, Aguilar MI, and Wu YQ (2008) Surface plasmon resonance assay for chloramphenicol. *Analyt Chem* 80: 8329-8333.
- Yuan J, Oliver R, Li J, Lee J, Aguilar M, and Wu Y (2007) Sensitivity enhancement of SPR assay of progesterone based on mixed self-assembled monolayers using nanogold particles. *Biosens Bioelectron* 23: 144-148.
- Zhang H, She Z, Su H, Kerman K, and Kraatz H-B (2016) Effects of bipyramidal gold nanoparticles and gold nanorods on the detection of immunoglobulins. *Analyst* 141: 6080-6086.

**DMD # 86249**

---

**Footnotes:**

This work was supported by the National Natural Science Foundation of People's Republic of China [Grants30873113, 81603183].

This work was supported by the National Major Scientific and Technological Special Project for Significant New Drugs Development [Grant 2018ZX09J18102].

## DMD # 86249

---

### Legends for Figures

**Figure 1.** Standard curve of C225 quantified by the gold nanoparticle-functionalized surface plasmon resonance assay and ELISA-based method in 20% monkey serum. The fitted curve was based on the four-parameter sigmoid model (mean  $\pm$  SD, n=6).

**Figure 2.** Signal responses of the baseline after each regeneration (a) and signal response of C225 at the first and 100<sup>th</sup> regeneration cycles at three different concentrations (b).

**Figure 3.** Serum concentration-time profiles of C225 in rhesus monkeys during and after intravenous infusion administration at 7.5, 24 and 75 mg/kg. The symbols represent the observed data (mean  $\pm$  SD, n=3).

**DMD # 86249**

**Table 1. LLOQ evaluation**

Nominal Concentration (µg/mL)	Observed Concentration (µg/mL)	CV (%)	Accuracy (%)
0.0125	0.0117	12.60	108.80
	0.0132		
	0.0125		
	0.0146		
	0.0160		

**DMD # 86249**

**Table 2. Determination of the precision and accuracy of the intraday assay**

Intr aday assay			
Nominal Concentration	0.025	0.4	1.6
of C225	(µg/mL)	(µg/mL)	(µg/mL)
	0.020	0.413	1.801
	0.028	0.392	1.862
Observed Concentration	0.024	0.392	1.671
of C225	0.021	0.397	1.586
	0.025	0.428	1.603
	0.027	0.380	1.541
Mean	0.024	0.400	1.677
SD	0.003	0.017	0.128
Precision (%)	13.20	4.31	7.63
Accuracy (%)	96.67	100.08	104.83

**DMD # 86249**

**Table 3. Determination of the precision and accuracy of the interday assay**

Nominal Concentration of C225	Interday assay		
	0.025 (µg/mL)	0.4 (µg/mL)	1.6 (µg/mL)
Observed Concentration of C225	0.023	0.406	1.816
	0.022	0.358	1.621
	0.028	0.411	1.909
	0.023	0.408	1.653
	0.024	0.413	1.742
Mean	0.024	0.399	1.748
SD	0.002	0.023	0.118
Precision (%)	9.77	5.81	6.75
Accuracy (%)	96.0	99.8	109.26

**DMD # 86249**

**Table 4. Effects of different matrices on the binding of C225 to the sensor surface**

(mean  $\pm$  SD, n=3)

Concentration of C225 (0.4 $\mu$ g/mL)	Observed Concentration ( $\mu$ g/mL, mean $\pm$ SD)	Precision (%)	Accuracy (%)
50% human serum	0.432 $\pm$ 0.027	6.25	108.0
50% Sprague Dawley rat serum	0.442 $\pm$ 0.057	12.93	110.5
20% monkey serum containing 0.4 $\mu$ g/mL chimeric recombinant anti-CD20 monoclonal antibody	0.424 $\pm$ 0.021	4.84	106.0
20% monkey serum containing 0.4 $\mu$ g/mL human $\gamma$ -globulin	0.439 $\pm$ 0.064	14.47	109.8
20% monkey serum containing 0.4 $\mu$ g/mL chimeric recombinant her 2 antibody	0.458 $\pm$ 0.040	8.64	114.5

**DMD # 86249**

**Table 5. Pharmacokinetic parameters of C225 in rhesus monkeys after intravenous infusion (n=3)**

	Low dose 7.5 mg/kg	Middle dose 24 mg/kg	High dose 75 mg/kg
AUC <sub>(0-t)</sub> (μg·h·mL <sup>-1</sup> )	16390 ± 1201.8	51453 ± 1199.8	263091 ± 30698
AUC <sub>(0-inf)</sub> (μg·h·mL <sup>-1</sup> )	16396 ± 1202.7	51526 ± 1198.8	26345 ± 30673
MRT (h)	105.11 ± 4.78	118.89 ± 1.19	152.84 ± 6.83
CL (mL·h <sup>-1</sup> ·kg <sup>-1</sup> )	0.459 ± 0.03	0.466 ± 0.01	0.29 ± 0.03
V <sub>ss</sub> (mL·kg <sup>-1</sup> )	48.26 ± 4.31	55.39 ± 0.94	43.85 ± 4.61
t <sub>1/2</sub> (h)	33.15 ± 1.82	48.03 ± 0.69	55.72 ± 0.73
C <sub>max</sub> (μg·mL <sup>-1</sup> )	160.57 ± 25.66	1459.5 ± 52.27	3750.0 ± 138.42

DMD # 86249

## Figures




Fig.1

DMD # 86249




Fig. 2

DMD # 86249




Fig. 3

Development of a gold nanoparticle-functionalized surface plasmon resonance assay for the sensitive detection of monoclonal antibodies and its application in pharmacokinetics

Haihong Bai, Mei Yuan, Xiaojing Wang, Xinghe Wang, Jinjing Che

Drug Metabolism and Disposition

Supplemental Figure 1 Serum concentration-time profiles of Erbitux and C225 in rhesus monkeys during and after intravenous infusion administration at 7.5 mg/kg by SPR assay. The symbols represent the observed data (mean  $\pm$  SD, n=3).

